Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53 -deficient B-cell malignancies

Blood (2022) 139 (25): 3617–3629.

https://doi.org/10.1182/blood.2021014007

Published: 2022

Includes: Supplemental data

Journal Articles

MARCKS affects cell motility and response to BTK inhibitors in CLL

Blood (2021) 138 (7): 544–556.

https://doi.org/10.1182/blood.2020009165

Published: 2021

Includes: Supplemental data

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

IL10RA modulates crizotinib sensitivity in NPM1-ALK + anaplastic large cell lymphoma

Blood (2020) 136 (14): 1657–1669.

https://doi.org/10.1182/blood.2019003793

Published: 2020

Includes: Supplemental data

Journal Articles

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Philipp Bernhard Staber, MD PhD, Christoph Kornauth, Ines Garces de los Fayos Alonso, Wilhelm Woessmann, MD, Wolfram Klapper, Sabine Lagger, Ana-Iris Schiefer, Cathrin Skrabs, Olaf Merkel, PhD, Marius E Mayerhoefer, Richard Greil, MD, Ingrid Simonitsch-Klupp, MD, Lukas Kenner, MD, Ulrich Jaeger, MD

Blood (2019) 134 (Supplement_1): 4037.

https://doi.org/10.1182/blood-2019-129955

Published: 2019

Journal Articles

Analysis of Mutational Landscape in Systemic Anaplastic Large Cell Lymphoma Identifies Novel Prognostic Markers

Blood (2019) 134 (Supplement_1): 1490.

https://doi.org/10.1182/blood-2019-126501

Published: 2019

Journal Articles

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

Stephen P. Ducray, BSc, Ricky Trigg, PhD, Andrew J. Bannister, PhD, Raymond Lai, MD PhD FRCP, Gerda Egger, PhD, Olaf Merkel, PhD, Lukas Kenner, MD, Suzanne Turner, PhD

Blood (2019) 134 (Supplement_1): 1483.

https://doi.org/10.1182/blood-2019-125648

Published: 2019

Journal Articles

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

Blood (2018) 132 (22): 2389–2400.

https://doi.org/10.1182/blood-2018-06-855502

Published: 2018

Includes: Supplemental data

Journal Articles

FcmR Shapes BCR Signaling in IgM-Positive Leukemia

Alexandra da Palma Guerreiro, PhD, Cornelia Dorweiler, Ismini Halmer, Olaf Merkel, Elena Maria Hartmann, MD, Valeska Berg, PhD, Nina Reinart, Günter Fingerle-Rowson, MD PhD, Gero Knittel, MSc, Christian Pallasch, MD, Andreas Rosenwald, Christian Reinhardt, MD, Clemens-Martin Wendtner, Michael Hallek, MD, Lukas P. Frenzel, MD

Blood (2018) 132 (Supplement 1): 2620.

https://doi.org/10.1182/blood-2018-99-118352

Published: 2018

Journal Articles

Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL

Laura Beckmann, MD, Valeska Berg, PhD, Clarissa Dickhut, Johannes Bloehdorn, MD, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Malte Hülsemann, MD, Stefan Loroch, Olaf Merkel, Kirsten Fischer, MD, Clemens-Martin Wendtner, Stephan Stilgenbauer, Albert Sickmann, PhD, Michael Hallek, René Zahedi, PhD, Lukas P. Frenzel, MD

Blood (2018) 132 (Supplement 1): 583.

https://doi.org/10.1182/blood-2018-99-118235

Published: 2018

Journal Articles

First in Human Response of BCL-2 Inhibitor Venetoclax in T-Cell Prolymphocytic Leukemia

Bernd Boidol, Christoph Kornauth, MD, Emiel van der Kouwe, Nicole Prutsch, Lukas Kazianka, MD, Gregor Hoermann, MD, Georg Hopfinger, MD, Alexander Hauswirth, MD, Marie-Bernadette Aretin, Wolfgang R. Sperr, MD, Peter Valent, MD, Ingrid Simonitsch-Klupp, MD, Richard Morrigl, PhD, Olaf Merkel, PhD, Lukas Kenner, MD, Ulrich Jaeger, MD, Stefan Kubicek, PhD, Philipp Bernhard Staber, MD PhD

Blood (2017) 130 (Supplement 1): 575.

https://doi.org/10.1182/blood.V130.Suppl_1.575.575

Published: 2017

Journal Articles

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 855.

https://doi.org/10.1182/blood.V130.Suppl_1.855.855

Published: 2017

Journal Articles

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

Blood (2017) 130 (23): 2499–2503.

https://doi.org/10.1182/blood-2017-05-785683

Published: 2017

Includes: Supplemental data

Journal Articles

Loss of TOSO Promotes Richter's Transformation of TCL1A Driven CLL

Alexandra da Palma Guerreiro, PhD, Cornelia Dorweiler, Laurent Kintzelé, Dunja Baatout, M.Sc., Malte Huelsemann, Valeska Berg, PhD, Olaf Merkel, Nina Reinart, PhD, Guenter Fingerle-Rowson, MD PhD, Gero Knittel, Christian Pallasch, MD, Hans Christian Reinhardt, Clemens Martin Wendtner, MD, Michael Hallek, Lukas P. Frenzel, MD

Blood (2016) 128 (22): 354.

https://doi.org/10.1182/blood.V128.22.354.354

Published: 2016

Journal Articles

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma

Blood (2015) 125 (1): 124–132.

https://doi.org/10.1182/blood-2014-08-594507

Published: 2015

Includes: Supplemental data

Journal Articles

Systematic Mapping Of Drug and Pathway Sensitivity In Chronic Lymphocytic Leukemia Identifies Synthetic Lethal Interactions Of Mutant p53

Leopold Sellner, MD, Oles Malgorzata, Mikolaj Slabicki, PhD, Carolin Blume, Hüllein Jennifer, Tatjana Stolz, Martin Sill, PhD, Sascha Dietrich, MD, Olaf Merkel, PhD, Anna Jauch, PhD, Manfred Hensel, MD, Davide Rossi, Zirlik Katja, MD, Martina Seiffert, PhD, Anthony D. Ho, MD, von Kalle Christof, MD, Hanno Glimm, MD, Wolfgang Huber, PhD, Thorsten Zenz, MD

Blood (2013) 122 (21): 173.

https://doi.org/10.1182/blood.V122.21.173.173

Published: 2013

Journal Articles

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia

Daniela Asslaber, Josefina D. Piñón, Irina Seyfried, Petra Desch, Markus Stöcher, Inge Tinhofer, Alexander Egle, Olaf Merkel, Richard Greil

Blood (2010) 115 (21): 4191–4197.

https://doi.org/10.1182/blood-2009-07-234823

Published: 2010

NARROW

Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53 -deficient B-cell malignancies

MARCKS affects cell motility and response to BTK inhibitors in CLL

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

IL10RA modulates crizotinib sensitivity in NPM1-ALK + anaplastic large cell lymphoma

Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR

Analysis of Mutational Landscape in Systemic Anaplastic Large Cell Lymphoma Identifies Novel Prognostic Markers

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

FcmR Shapes BCR Signaling in IgM-Positive Leukemia

Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL

First in Human Response of BCL-2 Inhibitor Venetoclax in T-Cell Prolymphocytic Leukemia

Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia

Loss of TOSO Promotes Richter's Transformation of TCL1A Driven CLL

Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma

Systematic Mapping Of Drug and Pathway Sensitivity In Chronic Lymphocytic Leukemia Identifies Synthetic Lethal Interactions Of Mutant p53

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only